Source: CureToday articles
Treatment with the Avmapki Fakzynja Co-pack received accelerated FDA approval for previously treated low-grade serous ovarian cancer with KRAS mutations.
Recent Content
- Vitamin B Supplements Could Aid Glaucoma, Slowing Disease Progression
- FDA Approves Avutometinib/Defactinib for Adults With KRAS-Mutated Recurrent LGSOC
- Obicetrapib Plus Ezetimibe Reduced LDL-C in Patients With or at Risk of Atherosclerotic Cardiovascular Disease
- NCPA: Any Pharma Tariffs Should Be Tailored to Avoid Increasing Shortages and Costs
- Biomarker Testing Remains Crucial for Young Patients With Lung Cancer
- How Cancer Care Teams Can Help With the Cessation of Smoking
- Asembia AXS25: Navigating the Transformative Landscape of GLP-1 Medications
- The Role of Physical Activity in Breast Cancer Risk Reduction and Survival
- B4DT Cognitive Behavioral Therapy Has Sustained Treatment Effects in Patients With Panic Disorders
- Coalition of Pharmacy Organizations Urges Congress to Pass ECAPS Legislation